This year marks the 10th anniversary of the publication of the first genome-wide association study (GWAS) in multiple sclerosis (MS), which facilitated a first glimpse into what constitutes genomic risk for MS outside the human leukocyte antigen (HLA) region. 1 Since, further GWASs using higher density single-nucleotide polymorphism (SNP) genotyping arrays in larger case-control sets, targeted studies, such as the Immunochip, and meta-analyses of genome scans have rapidly added new independent polymorphic risk variants. 2 The latest study 3 provides the highest resolution genomic map of MS to date, reporting 200 non-major histocompatibility complex (MHC) autosomal risk variants, for the first time, 1 chromosome X variant and over 30 independent associated variants within the extended MHC region following analysis in more than 110,000 subjects.
GWASs have greatly advanced our understanding of many complex diseases by revealing the polygenic basis of genomic risk. They did this by delivering consistently highly reproducible SNP-trait associations as long as adequate sample sizes were used. GWASs also revealed widespread pleiotropy among multiple diseases 4 and showed that subsets of variants are shared across spectra of autoimmune conditions including MS.
In the format implemented over the past decade, GWASs detected mainly common variants of small effect, whose combined effects can only partially explain heritability of the complex trait, and this was found to be the case for most complex conditions studied. Due to inherent imperfect linkage disequilibrium (LD, low r 2 ) between a common variant with high allele frequency and a rare causal variant, these arrays miss power to detect associations conferred by putative rare variants with stronger effects. Statistical imputation may recover information of relatively rare variants, but whole-genome sequencing (WGS) is more powerful for identification of very infrequent risk variants as long as their effect sizes are very large. 4 Huge sample sizes will be crucial for this to be successful, and these may concurrently be used for identification of new common risk loci with still smaller effect sizes (odds ratio (OR) < 1.05). Nevertheless, current evidence suggests that rare coding variants do not fully account for "missing heritability" in complex disorders, and that signals of common variants captured by SNP arrays are, in fact, due to LD with widespread relatively highly frequent causal alleles. 5 Estimates from current data sets suggest that rare larger effect variants appear to contribute more to genetic variance of motor neuron disease, schizophrenia, and autism than that of immune disorders. 4 In MS, common prioritized suggestive SNPs (i.e. that do not meet the strict threshold of genomewide significance at p < 5 × 10 −8 ) added 9% to the heritability conferred by genome-wide and extended MHC risk alleles to reach an overall score of 48%. 3 Future GWAS studies may validate such variants with genome-wide significance, discover new ones with ever smaller effects, and if informed by WGS or whole-exome sequencing (WES), identify low-frequent larger effect variants, all under the assumption that the required sample sizes of cases can be accumulated. Accordingly, when applied to MS, these GWASs may increase the number of predominantly very weak risk variants, which are unlikely to add much additional impact in terms of patient-oriented measures such as predictive tests.
Given these considerations and a finite budget, the main priority now is to translate genome-based information into biological relevant knowledge. This involves a multifaceted pipeline for deciphering true causal associations starting with fine-mapping strategies. 6 Distinct omics and in silico methods and other techniques are available to assess functional effects. For instance, expression quantitative trait locus (eQTL) studies link transcripts in specific cell types to complex traits, while quantitative isoform-specific information by RNA-Seq can identify splicing quantitative trait loci (sQTLs). Epigenetic changes modulated by genetic variants may reveal disease-associated modifications in transcriptional pathways. 5 Functionality of candidate regulatory variants can now also be studied by direct
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Correspondence to: K Vandenbroeck Dpto de Neurociencias -UPV/EHU, Achucarro Basque Center for Neuroscience, Lab R5, Parque Científico de la UPV/ EHU, Edificio Sede, planta 3, Barrio Sarriena, s/n 48940 Leioa (Bizkaia). k.vandenbroeck@ ikerbasque.org genome-editing techniques such as CRISPR/Cas9. A portion of target genes affected by risk QTLs code for proteins with as yet unknown or poorly understood biological functions, such as ANKRD55; hence, clarification from scratch of the biology of sometimes multiple co-produced isoforms is required. 7 In MS, cellular targets to be scrutinized by combinations of these and other approaches not only include cells of the peripheral immune system, CD4 + T cells, and monocytes but also central nervous system (CNS)-resident cells such as microglia and activated astrocytes. [1] [2] [3] Thus, an elaborate and multipronged experimental design is needed to fully understand the biological repercussions of the causal variant starting from the associated variant. This takes time to complete, and this may explain at least in part why GWAS follow-up research articles into individual complex disease genes are relatively scarce. 8 The case of IL7R illustrates this. A risk SNP located in the sixth exon of the gene was reported in 2007 in various studies, 1-2 and although non-synonymous in nature, the risk allele of this SNP did not alter IL-7 signaling but enhanced skipping of exon 6, promoting the proportion of messenger RNA (mRNA) coding for a secreted form of the receptor. A report published in 2013 revealed that this soluble form has moderate affinity for IL-7 and that it competed with the cell surface IL-7 receptor to sequester excess IL-7 thus potentiating its bioactivity. 9 This year, the risk allele of a SNP in the gene coding for the RNA helicase DDX39B was reported to act in concert with the IL7R risk allele to increasing skipping of exon 6, and thus biogenesis of the soluble form of the IL-7 receptor, via biological epistasis. 10 In conclusion, over the past decade, a plethora of GWAS studies has uncovered the genomic blueprints of many complex conditions and traits; the GWAS approach can thus rightly considered to be the defining feature of that era, but further progress will be highly dependent on dissection of the functional impacts of individual risk variants and on identification of key pathways and processes driving disease.
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